Drug Profile
GSK 2646264
Alternative Names: GSK2646264Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antiallergics; Skin disorder therapies
- Mechanism of Action Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cutaneous lupus erythematosus; Urticaria
Most Recent Events
- 24 Aug 2023 Discontinued - Phase-I for Cutaneous lupus erythematosus in Germany (Topical) (GSK pipeline, August 2023)
- 24 Aug 2023 Discontinued - Phase-I for Urticaria in Germany, United Kingdom (Topical) (GSK pipeline, August 2023)
- 24 Aug 2023 Discontinued - Preclinical for Cutaneous lupus erythematosus in United Kingdom (Topical) (GSK pipeline, August 2023)